Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15449452 | 1.00 | TSHR (0.47) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL11784960 | 0.87 | TSHR (0.46) | TSHRALDH1A1TDP1ALOX15RECQL | |
| SCHEMBL820889 | 0.87 | TSHR (0.46) | TSHRALDH1A1TDP1ALOX15RECQL | |
| SCHEMBL821048 | 0.87 | TSHR (0.46) | TSHRALDH1A1TDP1ALOX15RECQL | |
| SCHEMBL820895 | 0.87 | TSHR (0.46) | TSHRALDH1A1TDP1ALOX15RECQL | |
| SCHEMBL820982 | 0.83 | TSHR (0.67) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL2726 | 0.83 | TSHR (0.67) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL351491 | 0.83 | TSHR (0.67) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL509417 | 0.83 | TSHR (0.67) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL30554051 | 0.83 | TSHR (0.67) | TSHRTP53EGLN1EGLN3PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-9969669-B2 | Method for producing muconic acids and furans from aldaric acids | TEKNOLOGIAN TUTKIMUSKESKUS VTT OY (FI) | 2018-05-15 | — | — | US | disclosed |
| US-20170137363-A1 | Method for producing muconic acids and furans from aldaric acids | TEKNOLOGIAN TUTKIMUSKESKUS VTT OY (FI) | 2017-05-18 | — | — | US | disclosed |
| US-9177773-B2 | Systems and methods extending the laserspray ionization mass spectrometry concept from atmospheric pressure to vacuum | WAYNE STATE UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150053854-A1 | SYSTEMS AND METHODS EXTENDING THE LASERSPRAY IONIZATION MASS SPECTROMETRY CONCEPT FROM ATMOSPHERIC PRESSURE TO VACUUM | WAYNE STATE UNIVERSITY (US) | 2015-02-26 | — | — | US | disclosed |
| US-8853621-B2 | Systems and methods extending the laserspray ionization mass spectrometry concept from atmospheric pressure to vacuum | WAYNE STATE UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-8778645-B2 | Method for the production of glutaconate | BASF SE (DE) | 2014-07-15 | — | — | US | disclosed |
| US-20140027631-A1 | Systems and Methods Extending the Laserspray Ionization Mass Spectrometry Concept from Atmospheric Pressure to Vacuum | WAYNE STATE UNIVERSITY (US) | 2014-01-30 | — | — | US | disclosed |
| US-20120021472-A1 | Method for the Production of Glutaconate | BASF SE (DE) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | TSHR 2184/4885TP53 449/4885EGLN1 4273/4885 |
| US-20170137363-A1 | Method for producing muconic acids and furans from aldaric acids | ACSL6, FASN, CYP2A6 | TSHR 2959/4885TP53 2122/4885EGLN1 2876/4885 |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | TSHR 2359/4885TP53 2043/4885EGLN1 3225/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | TSHR 2184/4885TP53 449/4885EGLN1 4273/4885 |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | TSHR 2359/4885TP53 2043/4885EGLN1 3225/4885 |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | ENTPD1, ENTPD2, ENTPD5 | TSHR 3422/4885TP53 2940/4885EGLN1 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.